29. Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, Richard-Bulteau H, Vignaud A, Baas D, Defour A, Freyssenet D, Tanti JF, Le-Marchand-Brustel Y, Ferrier B, Conjard-Duplany A, Romanino K, Bauche S, Hantai D, Mueller M, Kozma SC, Thomas G, Ruegg MA, Ferry A, Pende M, Bigard X, Koulmann N, Schaeffer L, Gangloff YG. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. JCell Biol 2009; 187:859-874
30. Ohanna M, Sobering AK, Lapointe T, Lorenzo L, Praud C, Petroulakis E, Sonenberg N, Kelly PA, Sotiropoulos A, Pende M. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. NatCell Biol 2005; 7:286-294
31. Barbe C, Kalista S, Loumaye A, Ritvos O, Lause P, Ferracin B, Thissen JP. Role of IGF-I in the Follistatin-induced skeletal muscle hypertrophy. American journal of physiology Endocrinology and metabolism 2015:ajpendo 00098 02015
32. Serra C, Bhasin S, Tangherlini F, Barton ER, Ganno M, Zhang A, Shansky J, Vandenburgh HH, Travison TG, Jasuja R, Morris C. The role of GH and IGF-I in mediating anabolic effects of testosterone on androgen-responsive muscle. Endocrinology 2011; 152:193-206 33. Spangenburg EE, Le RD, Ward CW, Bodine SC. A functional insulin-like growth factor
receptor is not necessary for load-induced skeletal muscle hypertrophy. JPhysiol 2008; 586:283-291
34. Drummond MJ, Fry CS, Glynn EL, Dreyer HC, Dhanani S, Timmerman KL, Volpi E, Rasmussen BB. Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis. JPhysiol 2009; 587:1535-1546
35. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. NatCell Biol 2001; 3:1014-1019
36. Hornberger TA, Stuppard R, Conley KE, Fedele MJ, Fiorotto ML, Chin ER, Esser KA. Mechanical stimuli regulate rapamycin-sensitive signalling by a phosphoinositide 3-kinase-, protein kinase B- and growth factor-independent mechanism. The Biochemical journal 2004; 380:795-804
37. Matheny RW, Merritt E, Zannikos SV, Farrar RP, Adamo ML. Serum IGF-I-deficiency does
not prevent compensatory skeletal muscle hypertrophy in resistance exercise. Experimental biology and medicine 2009; 234:164-170
38. Yamaguchi A, Sakuma K, Morita I, Soya H, Takeda H, Katsuta S. Changes in fibre types in rat soleus and plantaris muscles following hypophysectomy and compensatory overload. Acta physiologica Scandinavica 1996; 158:89-95
39. Fortes MA, Pinheiro CH, Guimaraes-Ferreira L, Vitzel KF, Vasconcelos DA, Curi R. Overload- induced skeletal muscle hypertrophy is not impaired in STZ-diabetic rats. Physiological reports 2015; 3
40. Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI, Le RD. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001; 15:1926-1934
41. Goldberg AL. Work-induced growth of skeletal muscle in normal and hypophysectomized
rats. The American journal of physiology 1967; 213:1193-1198
42. Holzenberger M, Hamard G, Zaoui R, Leneuve P, Ducos B, Beccavin C, Perin L, Le Bouc Y. Experimental IGF-I receptor deficiency generates a sexually dimorphic pattern of organ- specific growth deficits in mice, affecting fat tissue in particular. Endocrinology 2001; 142:4469-4478
43. Begemann M, Zirn B, Santen G, Wirthgen E, Soellner L, Buttel HM, Schweizer R, van Workum W, Binder G, Eggermann T. Paternally Inherited IGF2 Mutation and Growth Restriction. The New England journal of medicine 2015; 373:349-356
44. Yakar S, Adamo ML. Insulin-like growth factor 1 physiology: lessons from mouse models. Endocrinology and metabolism clinics of North America 2012; 41:231-247, v
45. Wang Q, Guo T, Portas J, McPherron AC. A soluble activin receptor type IIb does not improve blood glucose in streptozotocin-treated mice. International journal of biological sciences 2015; 11:199-208
46. Boni-Schnetzler M, Schmid C, Meier PJ, Froesch ER. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. The American journal of physiology 1991; 260:E846-851 47. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces
Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. AmJPhysiol Cell Physiol 2009; 296:C1258-C1270
48. Goncalves MD, Pistilli EE, Balduzzi A, Birnbaum MJ, Lachey J, Khurana TS, Ahima RS. Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition. PLoSOne 2010; 5:e12707
49. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, Sandri M. Smad2 and
3 transcription factors control muscle mass in adulthood. AmJPhysiol Cell Physiol 2009; 296:C1248-C1257
50. Winbanks CE, Weeks KL, Thomson RE, Sepulveda PV, Beyer C, Qian H, Chen JL, Allen JM,
Lancaster GI, Febbraio MA, Harrison CA, McMullen JR, Chamberlain JS, Gregorevic P. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. The Journal of cell biology 2012; 197:997-1008
51. Yea SS, Fruman DA. Cell signaling. New mTOR targets Grb attention. Science 2011; 332:1270-1271
52. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. JClinInvest 2011; 121:1231-1241
53. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Dorfman AL, Longnus S, Pende M, Martin KA, Blenis J, Thomas G, Izumo S. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor- phosphoinositide 3-kinase-induced cardiac hypertrophy. MolCell Biol 2004; 24:6231-6240 54. Aguilar V, Alliouachene S, Sotiropoulos A, Sobering A, Athea Y, Djouadi F, Miraux S,
Thiaudiere E, Foretz M, Viollet B, Diolez P, Bastin J, Benit P, Rustin P, Carling D, Sandri M, Ventura-Clapier R, Pende M. S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab 2007; 5:476-487
55. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, O'Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochemical and biophysical research communications 2003; 300:965-971
56. Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C, Boue D, Martin PT, Sahenk Z, Mendell JR, Kaspar BK. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. ProcNatlAcadSciUSA 2008; 105:4318- 4322
57. Mendias CL, Marcin JE, Calerdon DR, Faulkner JA. Contractile properties of EDL and soleus muscles of myostatin-deficient mice. Journal of applied physiology 2006; 101:898-905 58. Amthor H, Macharia R, Navarrete R, Schuelke M, Brown SC, Otto A, Voit T, Muntoni F,
Vrbova G, Partridge T, Zammit P, Bunger L, Patel K. Lack of myostatin results in excessive muscle growth but impaired force generation. ProcNatlAcadSciUSA 2007; 104:1835-1840
59. Personius KE, Jayaram A, Krull D, Brown R, Xu T, Han B, Burgess K, Storey C, Shah B, Tawil R, Welle S. Grip force, EDL contractile properties, and voluntary wheel running after postdevelopmental myostatin depletion in mice. Journal of applied physiology 2010; 109:886-894
60. Gentry BA, Ferreira JA, Phillips CL, Brown M. Hindlimb skeletal muscle function in myostatin-deficient mice. Muscle Nerve 2011; 43:49-57
61. Ploquin C, Chabi B, Fouret G, Vernus B, Feillet-Coudray C, Coudray C, Bonnieu A, Ramonatxo C. Lack of myostatin alters intermyofibrillar mitochondria activity, unbalances redox status, and impairs tolerance to chronic repetitive contractions in muscle. American journal of physiology Endocrinology and metabolism 2012; 302:E1000-1008
62. Kandarian SC, White TP. Mechanical deficit persists during long-term muscle hypertrophy. Journal of applied physiology 1990; 69:861-867
63. Mendias CL, Kayupov E, Bradley JR, Brooks SV, Claflin DR. Decreased specific force and power production of muscle fibers from myostatin-deficient mice are associated with a suppression of protein degradation. Journal of applied physiology 2011; 111:185-191 64. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER,
Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. NatGenet 2001; 27:195-200
65. Qaisar R, Renaud G, Morine K, Barton ER, Sweeney HL, Larsson L. Is functional hypertrophy and specific force coupled with the addition of myonuclei at the single muscle fiber level? FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2012; 26:1077-1085
66. Matsakas A, Macharia R, Otto A, Elashry MI, Mouisel E, Romanello V, Sartori R, Amthor H, Sandri M, Narkar V, Patel K. Exercise training attenuates the hypermuscular phenotype and restores skeletal muscle function in the myostatin null mouse. Experimental physiology 2012; 97:125-140
67. Matsakas A, Romanello V, Sartori R, Masiero E, Macharia R, Otto A, Elashry M, Sandri M, Patel K. Food restriction reverses the hyper-muscular phenotype and force generation capacity deficit of the myostatin null mouse. International journal of sports medicine 2013; 34:223-231
68. Savage KJ, McPherron AC. Endurance exercise training in myostatin null mice. Muscle Nerve 2010; 42:355-362
69. Matsakas A, Mouisel E, Amthor H, Patel K. Myostatin knockout mice increase oxidative muscle phenotype as an adaptive response to exercise. JMuscle ResCell Motil 2010; 31:111- 125
70. Xin M, Kim Y, Sutherland LB, Qi X, McAnally J, Schwartz RJ, Richardson JA, Bassel-Duby R, Olson EN. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Science signaling 2011; 4:ra70
71. Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Ma H, Pierre P, Pasternack A, Kainulainen H, Ritvos O. Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins. American journal of physiology Endocrinology and metabolism 2013; 304:E41-50
72. Goodman CA, Dietz JM, Jacobs BL, McNally RM, You JS, Hornberger TA. Yes-Associated Protein is up-regulated by mechanical overload and is sufficient to induce skeletal muscle hypertrophy. FEBS letters 2015; 589:1491-1497
73. Judson RN, Tremblay AM, Knopp P, White RB, Urcia R, De Bari C, Zammit PS, Camargo FD, Wackerhage H. The Hippo pathway member Yap plays a key role in influencing fate decisions in muscle satellite cells. Journal of cell science 2012; 125:6009-6019
74. Watt KI, Turner BJ, Hagg A, Zhang X, Davey JR, Qian H, Beyer C, Winbanks CE, Harvey KF, Gregorevic P. The Hippo pathway effector YAP is a critical regulator of skeletal muscle fibre size. Nature communications 2015; 6:6048
75. Schakman O, Kalista S, Bertrand L, Lause P, Verniers J, Ketelslegers JM, Thissen JP. Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology 2008; 149:3900- 3908
76. Yang W, Zhang Y, Li Y, Wu Z, Zhu D. Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1. JBiolChem 2007; 282:3799-3808
77. Steelman CA, Recknor JC, Nettleton D, Reecy JM. Transcriptional profiling of myostatin- knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006; 20:580-582
78. Bernardi H, Gay S, Fedon Y, Vernus B, Bonnieu A, Bacou F. Wnt4 activates the canonical beta-catenin pathway and regulates negatively myostatin: functional implication in myogenesis. American journal of physiology Cell physiology 2011; 300:C1122-1138 79. von Maltzahn J, Bentzinger CF, Rudnicki MA. Wnt7a-Fzd7 signalling directly activates the
Akt/mTOR anabolic growth pathway in skeletal muscle. Nature cell biology 2012; 14:186- 191
80. Sartori R, Schirwis E, Blaauw B, Bortolanza S, Zhao J, Enzo E, Stantzou A, Mouisel E, Toniolo L, Ferry A, Stricker S, Goldberg AL, Dupont S, Piccolo S, Amthor H, Sandri M. BMP signaling controls muscle mass. Nature genetics 2013; 45:1309-1318
81. Sartori R, Sandri M. BMPs and the muscle-bone connection. Bone 2015;
82. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and
promising therapies. Nature reviews Drug discovery 2015; 14:58-74
83. Gangopadhyay SS. Systemic administration of follistatin288 increases muscle mass and reduces fat accumulation in mice. Scientific reports 2013; 3:2441
84. Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 2006; 147:3586-3597
85. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, Wright JF, Barker C, Ehrmantraut G, Holmstrom J, Trowell B, Gertz B, Jiang MS, Sebald SM, Matzuk M, Li E, Liang LF, Quattlebaum E, Stotish RL, Wolfman NM. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. ProcNatlAcadSciUSA 2005; 102:18117- 18122
86. Sako D, Grinberg AV, Liu J, Davies MV, Castonguay R, Maniatis S, Andreucci AJ, Pobre EG, Tomkinson KN, Monnell TE, Ucran JA, Martinez-Hackert E, Pearsall RS, Underwood KW, Seehra J, Kumar R. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. The Journal of biological chemistry 2010; 285:21037- 21048
87. Gilson H, Schakman O, Kalista S, Lause P, Tsuchida K, Thissen JP. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. AmJPhysiol EndocrinolMetab 2009; 297:E157-E164
88. Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Annals of neurology 2002; 52:832-836
89. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS. Myostatin propeptide-
mediated amelioration of dystrophic pathophysiology. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005; 19:543-549
90. Morine KJ, Bish LT, Pendrak K, Sleeper MM, Barton ER, Sweeney HL. Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PloS one 2010; 5:e9176
91. Morine KJ, Bish LT, Selsby JT, Gazzara JA, Pendrak K, Sleeper MM, Barton ER, Lee SJ, Sweeney HL. Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve 2010; 42:722-730
92. George Carlson C, Bruemmer K, Sesti J, Stefanski C, Curtis H, Ucran J, Lachey J, Seehra JS. Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse. Muscle Nerve 2011; 43:694-699
93. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420:418-421
94. Pistilli EE, Bogdanovich S, Goncalves MD, Ahima RS, Lachey J, Seehra J, Khurana T. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. AmJPathol 2011; 178:1287-1297
95. Parsons SA, Millay DP, Sargent MA, McNally EM, Molkentin JD. Age-dependent effect of
myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. The American journal of pathology 2006; 168:1975-1985
96. Holzbaur EL, Howland DS, Weber N, Wallace K, She Y, Kwak S, Tchistiakova LA, Murphy E, Hinson J, Karim R, Tan XY, Kelley P, McGill KC, Williams G, Hobbs C, Doherty P, Zaleska MM, Pangalos MN, Walsh FS. Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiology of disease 2006; 23:697-707
97. Bogdanovich S, McNally EM, Khurana TS. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 2008; 37:308-316
98. Lee YS, Lehar A, Sebald S, Liu M, Swaggart KA, Talbot CC, Jr., Pytel P, Barton ER, McNally EM, Lee SJ. Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy. Human molecular genetics 2015;
99. Smith RC, Lin BK. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Current opinion in supportive and palliative care 2013; 7:352- 360
100. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM,
Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Annals of neurology 2008; 63:561-571
101. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142:531-543
102. Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochemical and biophysical research communications 2010; 391:1548-1554
103. Murphy KT, Koopman R, Naim T, Leger B, Trieu J, Ibebunjo C, Lynch GS. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2010; 24:4433-4442
104. Busquets S, Toledo M, Orpi M, Massa D, Porta M, Capdevila E, Padilla N, Frailis V, Lopez- Soriano FJ, Han HQ, Argiles JM. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. Journal of cachexia, sarcopenia and muscle 2012; 3:37-43
105. Gallot YS, Durieux AC, Castells J, Desgeorges MM, Vernus B, Plantureux L, Remond D, Jahnke VE, Lefai E, Dardevet D, Nemoz G, Schaeffer L, Bonnieu A, Freyssenet DG. Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer research 2014; 74:7344-7356
106. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. The Journal of nutrition 1999; 129:227S-237S
107. Gilson H, Schakman O, Combaret L, Lause P, Grobet L, Attaix D, Ketelslegers JM, Thissen JP. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 2007; 148:452-460
108. Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige JN, Hartmann S, Brachat S, Rivet H, Koelbing C, Morvan F, Hatakeyama S, Glass DJ. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Molecular and cellular biology 2014; 34:606-618
109. LeBrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM, Brown TA. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. The journals of gerontology Series A, Biological sciences and medical sciences 2009; 64:940-948
110. Chiu CS, Peekhaus N, Weber H, Adamski S, Murray EM, Zhang HZ, Zhao JZ, Ernst R, Lineberger J, Huang L, Hampton R, Arnold BA, Vitelli S, Hamuro L, Wang WR, Wei N, Dillon GM, Miao J, Alves SE, Glantschnig H, Wang F, Wilkinson HA. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents. The journals of gerontology Series A, Biological sciences and medical sciences 2013; 68:1181-1192 111. Collins-Hooper H, Sartori R, Macharia R, Visanuvimol K, Foster K, Matsakas A, Flasskamp
H, Ray S, Dash PR, Sandri M, Patel K. Propeptide-mediated inhibition of myostatin increases